During the development of nephrotoxic nephritis (NTN) in the mouse, we find that a variety of chemokines and chemokine receptors are induced: CCR1 (RANTES, MIP-1α), CCR2 (MCP-1), CCR5 (RANTES, MIP-1α, MIP-1β), CXCR2 (MIP-2), and CXCR3 (IP-10). Their timing of expression indicated that CXCR2 and CCR1 are probably important in the neutrophil-dependent heterologous phase of the disease, whereas CCR1, CCR2, CCR5, and CXCR3 accompany the subsequent mononuclear cell infiltration characteristic of autologous disease. We therefore assessed the role of CCR1 in NTN using CCR1 -/-mice. We found that neutrophil accumulation in CCR1 -/-mice was comparable to that in wild-type animals but that renal recruitment of CD4 + and CD8 + T cells and macrophages increased significantly. Moreover, CCR1 -/-mice developed more severe glomerulonephritis than did controls, with greater proteinuria and blood urea nitrogen, as well as a higher frequency of crescent formation. In addition, CCR1 -/-mice showed enhanced Th1 immune responses, including titers of antigen-specific IgG2a antibody, delayed-type hypersensitivity responses, and production of IFN-γ and TNF-α. Lastly, using recombinant proteins and transfected cells that overexpressed CCR1, we demonstrated that MIP-1α, but not RANTES, bound CCR1 and induced cell chemotaxis. Thus, rather than simply promoting leukocyte recruitment during NTN, CCR1 expression profoundly alters the effector phase of glomerulonephritis. Therapeutic targeting of chemokine receptors may, on occasion, exacerbate underlying disease.
Introduction
Glomerular inflammation, crescent formation, and interstitial fibrosis, the cardinal pathologic features of rapidly progressive glomerulonephritis, are mediated in large part by the infiltration of monocytes and T cells (1, 2) . At least conceptually, such cellular infiltrate is thought to result from the coordinated action of multiple chemotactic factors, including leukotrienes, complement components, and chemokines (3) . Recently, attention has focused on the role of chemokines in this disease. Expression of several chemokines (MIP-1α, MIP-1β, MIP-2, RANTES, MCP-1, CINC, and IP-10) in rodent models of rapidly progressive glomerulonephritis is reported on (4) (5) (6) (7) (8) , and the functional importance of individual chemokines has in some cases been determined. For example, administration of a polyclonal antiserum to MIP-2 and CINC reduced glomerular neutrophil influx and proteinuria in the heterologous phase of rat nephrotoxic nephritis (NTN) (6, 9, 10) . In an accelerated model of NTN in CD1 mice, both a RANTES antagonist (met-RANTES) and anti-MCP-1 antibodies were shown to reduce proteinuria, T-cell and macrophage infiltration, and (in the case of anti-MCP-1 antibody therapy) glomerular crescent formation and interstitial fibrosis (11) . However, in a separate study of NTN in MCP-1-deficient mice, although tubulointerstitial injury was reduced, glomerular pathology was comparable to that of wildtype mice (12) , highlighting some of the potential problems of data interpretation that can arise in such studies. NTN is mouse strain-dependent, different nephrotoxic sera (NTS) have variable potencies, and intervention by gene deletion or neutralization with blocking antibodies or antagonists can lead to differing outcomes. Importantly, to date, no studies have used chemokine receptor-directed strategies.
Chemokines bind to and activate G protein-coupled chemokine receptors (13) . The expression of different chemokine receptors by leukocyte subsets provides a further level of regulation of leukocyte trafficking, and also appears to dictate the nature of the immune response. For example, CCR5 and CXCR3 are expressed primarily by activated T cells and are associated with a Th1 immune response, whereas CCR3 and CCR4 are associated with Th2 responses (14) . In this study, we analyzed the temporal expression of chemokine recep-tors in a mouse model of accelerated NTN, and based upon our initial data, we went on to define the role of CCR1, a receptor (at least in humans) for RANTES, MIP-1α, and other chemokines, using mice with a targeted disruption of this gene.
Methods

Preparation of NTS.
Sheep were immunized with a lysate of glomeruli prepared from Sprague-Dawley rat kidneys, as described (15) . NTS was heat-inactivated at 56°C for 45 minutes and then absorbed overnight with mouse red blood cells. Before use, the preparation was sterilized by passage through a 0.2-µm filter.
Induction of accelerated NTN. For studies of CCR1 in glomerulonephritis, mice with a targeted disruption of the CCR1 gene (CCR1 -/-) were used. Generation of these mice has been described previously (16) . They were of the same genetic background as the CCR1-sufficient (CCR1 +/+ ) mice used (B6/129, intercrossed 10-20 generations). Additional control inbred C57BL/6 mice, 129 mice, and B6/129 mice were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA). All mice were housed under specific pathogen-free conditions. Male CCR1 +/+ mice or CCR1 -/-mice (each weighing approximately 30 grams) were sensitized by subcutaneous injection of 1 mg normal sheep IgG in Freund's complete adjuvant in divided doses in each flank. Five days later, mice were injected with 0.1 mL of NTS daily for 3 days; control mice received normal sheep serum. At intervals from 3 to 21 days after the first dose of NTS, groups of mice (4-6 per group) were sacrificed, the kidneys were harvested, and blood was collected by cardiac puncture.
Immunopathology. Kidney halves were fixed overnight at 4°C in 10% neutral buffered formalin and then embedded in paraffin. Four-micrometer sections were cut and then stained with periodic acid-Schiff reagent and Masson's trichrome for routine histology. All morphologic evaluations were performed in a blinded fashion using 6-8 kidneys per group for each timepoint. Glomerular pathology was assessed by evaluating at least 100 glomeruli per kidney for hypercellularity, necrosis, hyalinosis, microaneurysms, and crescent formation. Interstitial injury was assessed by determining the proportion of cortical tubules with atrophy, dilatation, or necrosis.
The remaining kidney half was snap-frozen and stored at -70°C until sectioning for immunohistology. Monoclonal antibodies to mouse proteins and isotypematched control antibodies were purchased from PharMingen (San Diego, California, USA); these included monoclonal antibodies directed against all leukocytes (CD45, 30F11.1), T cells (CD4, GK1.5; and CD8, 53-6.7), monocytes and granulocytes (CD11b, M1/70), and granulocytes alone (GR-1, RB6-8C5). Cryostat sections were fixed in paraformaldehyde-lysineperiodate and stained using a 4-layer peroxidaseantiperoxidase technique (17) . For assessment of glomerular cellularity, ≥ 25 equatorially-sectioned glomeruli/kidney were examined. Results were expressed as cells per glomerular cross-section. For analysis of interstitial infiltrates, the number of positive cells per high power field (hpf; ×400) were counted (≥ 20 hpf/animal). For cell markers identifying dense or extensive infiltrates that precluded accurate individual cell counts, computer-aided image analysis was performed. For this purpose, 20 hpf/animal were captured by digital video microscopy and then analyzed using IPLab software (Scanalytics Inc., Fairfax, Virginia, USA); results were expressed as percent sectional area occupied by the immunostained cells.
Renal immunoglobulin and complement deposition. Cryostat sections of renal cortical tissues (4 samples/group, taken on days 3, 7, and 14) were incubated with serial dilutions of peroxidase-conjugated rabbit anti-sheep IgG and peroxidase-conjugated rat anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG2c, and C3 monoclonal antibodies (Zymed Laboratories Inc., South San Francisco, California, USA) and diaminobenzidine substrate (17) . Sections were evaluated for the greatest dilution at which C3 and linear glomerular immunoglobulin deposition (≥ 20 glomeruli/kidney) were still detectable. Renal function. Urinary protein excretion was measured at intervals from 0 to 21 days in overnight urine collections from mice housed in individual metabolic cages. During the urine collection, mice were allowed free access to water but not food. Protein concentration was assayed using the Microprotein PR reagent kit (Sigma Chemical Co., St. Louis, Missouri, USA). Blood urea nitrogen was measured on serum samples taken at intervals from 0 to 21 days using the urea nitrogen assay kit from Sigma Chemical Co.
Ribonuclease protection assays of chemokine and chemokine receptor expression. Whole kidney RNA was isolated by guanidine-thiocyanate extraction, acid phenol/chloroform extraction, and alcohol precipitation (18) ; RNA integrity was confirmed by agarose gel electrophoresis and was quantitated by optical density measurement at 260 nm. RNA from each mouse was evaluated using the RiboQuant system (PharMingen). Mouse template sets mCK5 and mCK3b were used for detection of chemokines and cytokines, respectively; template sets mCR5 and mCR6 were used to detect CC and CXC chemokine receptors, respectively. In addition, a riboprobe for mouse CXCR3 was prepared in-house. In vitro transcription was undertaken in transcription buffer supplemented with [α 32 P]UTP (3,000 Ci/mmol; Amersham Life Sciences Inc., Arlington Heights, Illinois, USA) and T7 RNA polymerase. After DNaseI treatment, the riboprobe was isolated by phenol/chloroform extraction and precipitation with ammonium acetate and ethanol; labeling efficiency was determined by measuring Cherenkov activity in a scintillation counter. Each riboprobe set was diluted to the optimal activity defined by the manufacturer, and then added to 20 µg of kidney RNA. This was heated to 90°C, allowed to cool to 56°C, and annealed overnight. After RNase and proteinase K treatment, protected RNA hybrids were purified by phenol/chloroform extraction and precipitation with ammonium acetate and ethanol, and then separated by electrophoresis on 5% polyacrylamide/8 M urea gels. Gels were dried and subjected to autoradiography using Kodak Biomax MS2 film (Eastman Kodak Co., Rochester, New York, USA). Autoradiographs were scanned and imported into Adobe Photoshop (Adobe Systems Inc., San Jose, California, USA). RNA bands were quantitated by densitometric analysis with NIH Image (National Institutes of Health, Bethesda, Maryland, USA), and results were normalized for L32 and GAPDH gene expression.
Skin delayed-type hypersensitivity responses to sheep IgG. Mice were challenged 48 hours before the end of each experiment by intradermal injection of sheep IgG (100 µg in 20 µL of PBS) into the footpad using a 30-gauge needle. The other foot was injected with an identical volume of PBS. Footpad swelling was measured 48 hours later using a micrometer. Results are expressed as antigen-specific swelling in micrometers, calculated as the difference in thickness between vehicle-and antigen-injected footpads.
Antigen-specific cytokine production by splenic T cells.
Spleens from sensitized CCR1 +/+ or CCR1 -/-mice were removed aseptically, and then placed in RPMI-1640/10% FCS medium and disrupted to form singlecell suspensions. Erythrocytes were depleted using Red Cell Lysis buffer (Sigma Chemical Co.). After washing in RPMI/FCS, each suspension was enriched for T cells using nylon wool columns (Polysciences Inc., Warrington, Pennsylvania, USA). Enriched T cells (4 × 10 6 cells/mL) were incubated for 72 hours in RPMI-1640/10% FCS in 96-well tissue culture plates with or without 20 µg/mL sheep IgG, and cell supernatants were assayed for IL-4, IFN-γ, and TNF-α by ELISA (Opt-EIA; PharMingen).
TNF-α production by splenic mononuclear cells. Single spleen cell suspensions were prepared from CCR1 +/+ or CCR1 -/-mice. Suspensions were then depleted of red cells and incubated in RPMI-1640/10% FCS medium containing LPS (1 µg/mL) for 3 hours at 37°C in an atmosphere of 5% CO 2 . Supernatant TNF-α levels were assayed by ELISA (PharMingen).
Mouse anti-sheep IgG antibody isotypes. Titers of mouse anti-sheep IgG antibody were measured by ELISA using sera collected at multiple timepoints. Microtiter plates were coated with 100 µL of 10 µg/mL sheep IgG in carbonate buffer (pH 9.6) overnight at 4°C. After blocking with 1% BSA in PBS, the plates were incubated with serial dilutions of mouse serum (starting at 1:100) for 2 hours at room temperature. Bound mouse IgG was detected using peroxidase-conjugated rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., Philadelphia, Pennsylvania, USA) at 1:2,000, orthopenyldiamine substrate, and absorbance readings (at 450 nm) on a spectrophotometer. Lack of cross-reactivity of the secondary antibody with sheep IgG was demonstrated by omitting the primary antibody. Immunoglobulin isotypes were measured using the ELISA technique already described. Mouse serum was diluted 1:100 for IgG1 and 1:20 for IgG2a; the bound mouse immunoglobulin isotypes were detected using peroxidase-conjugated rat anti-mouse IgG1 and IgG2a antibodies (Zymed Laboratories Inc.) at a dilution of 1:2,000.
Generation of murine CCR1 L1/2 stable cell transfectants. The coding region of mCCR1 was amplified by PCR and directionally cloned into the BamHI and NotI sites of pcDNA3 (Invitrogen Corp., San Diego, California, USA). Stable transfectant cell lines were generated in the murine pre-B lymphoma cell line L1/2 and cultured as described (19) . Cells were treated with butyric acid before performing experiments. Clones selected had approximately 100,000 sites/cell after overnight stimulation with butyric acid (10 mM), as determined by Scatchard analysis of binding data.
Chemokine synthesis. Murine RANTES and human and murine MIP-1α were synthesized by f-moc chemistry (using a 433A automated peptide synthesizer; PerkinElmer Biosystems, Norwalk, Connecticut, USA). Purification and folding was carried out as described (20) . The molecular integrity of each folded purified protein was determined by electron-spray mass spectrometry; all proteins had the expected specific activities. Murine recombinant MCP-3 was purchased from PeproTech Inc. (Rocky Hill, New Jersey, USA).
Chemotaxis assays. Biocoat Transwell culture inserts (3 µm; Corning-Costar Corp., Acton, Massachusetts, USA) were used for 24-well chemotaxis assays. Briefly, 10 6 cells in 100 µL of chemotaxis medium (50% M199, 50% RPMI-1640, and 0.5% BSA) were dispensed into the Transwell in the chemotaxis chamber. Then 600 µL of chemotaxis medium with or without chemokine was placed in the bottom well and cultures were incubated at 37°C for 5 hours or overnight. Cells that migrated to the bottom well were counted by flow cytometry. Relative cell counts were obtained by acquiring events for a set time of 30 seconds.
Competitive ligand binding assays. Human MIP-1α labeled with 125 I was used as the radioligand, and mMIP-1α, hMIP-1α, mRANTES, and mMCP-3 were the cold competitive ligands. Briefly, 10 5 cells were incubated for 45 minutes at ambient temperature with 0.05 nM radiolabeled ligand in the absence or presence of increasing concentrations of unlabeled chemokine. The binding reaction was carried out in binding buffer (50 mM HEPES at pH 7.5, 1 mM CaCl 2 , 5 mM MgCl 2 , 0.05% Na 3 N, and 0.5% BSA) in a total volume of 100 µL. Cells were washed 3 times with high-salt buffer (binding buffer containing 0.5 M NaCl), and cell-associated radioactivity was assessed in a scintillation radioactivity counter. Nonspecific binding was determined in the presence of 100 nM unlabeled chemokine. Specific binding was obtained by subtracting nonspecific binding from total binding using KaleidaGraph software (Synergy Software, Reading, Pennsylvania, USA).
Results
Chemokine and chemokine receptor mRNA expression during NTN. In preliminary studies, several chemokine receptor mRNA types were detected within nephritic kidneys, leading to consideration of the importance of each receptor using corresponding knockout mice. This first paper deals with the effects of absence of CCR1 on the pathogenesis of NTN; results are presented in each case with normal kidneys compared with corresponding nephritic kidneys generated in CCR1 +/+ and CCR1 -/-mice. In normal kidneys, low-level expression of RANTES, MIP-1β, MIP-2, eotaxin, and IP-10 mRNA was
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The observed ( Figure 1 ). Development of glomerular injury in CCR1 +/+ mice was associated with progressively increasing renal expression of multiple chemokine mRNAs, which typically peaked by 7 days after NTS treatment ( Figure 1) ; at day 7, significantly increased chemokine mRNAs (P < 0.05) included MCP-1 (11-fold), eotaxin (8-fold), IP-10 (6-fold), MIP-2 (6-fold), MIP-1β (4-fold), RANTES (3-fold), and MIP-1α (2-fold). TCA-3 mRNA (not shown) was unchanged during the experimental period. Chemokine mRNA data from nephritic CCR1 -/-mice were generally comparable to that of CCR1 +/+ mice, except for typically reduced mRNA expression at day 7 after NTS injection ( Figure 1 ). Analysis of chemokine receptor mRNA expression (Figure 2) showed serial increases of mRNA in CCR1 +/+ mice, in most cases peaking at day 7 after NTS injection, including CCR1 (12-fold increase over baseline), CCR5 (6-fold), CCR2 (4-fold), CXCR2 (4-fold), and CXCR3 (> 3-fold). Apart from CCR1 itself, CCR1 -/-mice showed decreased expression of CCR2 and CCR5 at day 7 after NTS injection compared with CCR1 +/+ mice (Figure 2 ), but comparable levels thereafter. However, with significance for future studies, levels of CXCR3 mRNA continued to rise in both groups throughout the course of study (Figure 2 ), whereas CCR3, CCR4, CXCR4, and CXCR5 mRNA expression remained at baseline levels.
CCR1 -/-mice develop greater renal impairment than do CCR1 +/+ mice. Given that CCR1 mRNA was the most abundantly induced chemokine receptor and was expressed at all timepoints examined in nephritic but not in baseline kidneys, we compared functional parameters in CCR1 -/-and CCR1 +/+ mice. Surprisingly, the absence of CCR1 resulted in more severe disease. In CCR1 -/-mice, both urine protein excretion (21.6 mg per 24 hours at day 7) and blood urea nitrogen (214 mg/dL at day 3) were greater than in CCR1 +/+ mice (respectively 5.8 mg per 24 hours at day 7, P < 0.01; 168 mg/dL at day 3, P < 0.01) (Figure 3) , and their elevations were more persistent (Figure 3 ). Comparable differences between CCR1 -/-mice and pure C57/BL6 or 129 mice after NTS injection were also noted (data not shown).
CCR1 -/-mice develop more severe crescentic glomerulonephritis than do CCR1 +/+ mice. Consistent with the renal function data, the severity of histologic injury was significantly greater in CCR1 -/-than in CCR +/+ mice. More CCR1 -/-mice developed crescents than did CCR1 +/+ mice (35% of CCR1 -/-mice vs. 17% of mice at day 21; P < 0.01). In addition, CCR1 -/-mice showed more glomerulosclerosis and glomerular hypercellularity, though several other parameters of glomerular injury (e.g., sclerosis, necrosis, and microaneurysm formation) and interstitial injury (not shown) were not significantly different between the 2 groups (Figure 4) . However, T-cell and macrophage infiltration of both glomerular and interstitial compartments was greater in CCR1 -/-mice throughout the course of renal disease (Figure 4) .
CCR1 -/-mice show a normal humoral immune response to sheep IgG. Humoral responses were examined as a potential explanation for the enhanced disease in CCR1 -/-mice compared with CR1 +/+ mice. Glomerular deposition of sheep IgG, mouse IgG, and complement was comparable between the 2 groups (data not shown). Furthermore, serum titers of total mouse antisheep IgG were comparable in the 2 groups (Figure 5a) .
CCR1 -/-mice show a Th1 antigen-specific immune response. Antigen-specific IgG isotype production in CCR1 -/-mice was consistent with a Th1-deviated response. Although IgG1 titers were comparable in both groups (Figure 5a ), the titers of IgG2a were significantly higher in the CCR1 -/-group (P < 0.01) (Figure 5a) . Cutaneous delayed-type hypersensitivity (DTH) responses upon intradermal challenge with sheep IgG were also significantly greater in CCR1 -/-mice than in CCR1 +/+ mice (P < 0.05) (Figure 5b ). This led us to examine cytokine production from T cell-enriched spleen cell cultures. IFN-γ production was significantly higher in CCR1 -/-mice than in control CCR1 +/+ mice (878 pg/mL vs. 597 pg/mL, respectively; P < 0.05) (Figure 5c ).
CCR1 -/-mice have enhanced mononuclear cell TNF-α production. Expression of TNF family genes was analyzed by ribonuclease protection assay. Figure 7 shows a representative autoradiograph demonstrating that TNF-α, TNF-β, and lymphotoxin-β are expressed at higher levels in CCR1 -/-mice than in CCR1 +/+ mice. In addition, isolated splenic mononuclear cells from CCR1 -/-mice produced more TNF-α in response to LPS than did CCR1 +/+ mononuclear cells (Figure 6 ).
MIP-1α is the predominant CCR1 ligand in mice.
Because CCR1 and at least 3 of its reported ligands (MIP-1α, MCP-3, and RANTES) are expressed in nephritic kidneys, we questioned why loss of CCR1 did not have an inhibitory effect on cell recruitment. Accordingly, the ligand specificity of mouse CCR1 was analyzed in vitro using mouse CCR1 transfectants in chemotaxis and ligand binding assays. These experiments demonstrated that mouse CCR1 transfectants were chemoattracted by mouse MIP-1α but not by mouse RANTES or MCP-3 (Figure 7a ), whereas in control wells, mouse RANTES induced a robust chemotactic response by mouse CCR5 transfectants and mouse MCP-3 chemoattracted mouse CCR3 transfectants (data not shown). Competitive binding assays using mouse CCR1 transfectants confirmed these results, demonstrating that mouse MIP-1α
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The Journal of Clinical Investigation | December 1999 | Volume 104 | Number 11 alone was able to competitively inhibit binding of radiolabeled human MIP-α, whereas mouse MCP-3 and mouse RANTES had no effect (Figure 7b ).
Discussion
To our knowledge, this is the first comprehensive analysis of the expression patterns and functional roles of chemokine receptors in any kidney disease model. Our rationale was to identify those chemokine receptors whose temporal expression would suggest involvement in the recruitment of specific leukocyte subsets to nephritic kidneys in a way that they could then be targeted by interventional studies using monoclonal antibodies or genetically deficient mice. The heterologous phase of mouse NTN involves neutrophil infiltration of glomeruli that begins within hours of NTS administration and lasts for several days (21, 22) . Although this phase of disease was not our prime interest given the key role of complement at this stage, the results at day 3 do provide some information about chemokine receptors that may be involved in neutrophil recruitment. Both CCR1 and CXCR2 were upregulated by day 3; it is known that mouse neutrophils express both of these receptors, so it is possible that they each contribute to this neutrophil-dependent phase of glomerular disease (23, 24) . However, no difference in the number of glomerular neutrophils was observed between CCR1 -/-and CCR1 +/+ mice at day 3 (data not shown), and the degree of early proteinuria was comparable in both groups. Because proteinuria during this early phase is at least in part due to neutrophil-mediated glomerular injury (21, 25) , these observations suggest that neutrophil recruitment is not dependent on CCR1 in this model. CXCR2 is an alternate chemokine receptor expressed by neutrophils, and it was previously shown in a rat model of NTN (9) that neutralization of MIP-2 (a CXCR2 ligand) using a polyclonal antiserum decreased neutrophil recruitment and proteinuria during the heterologous phase of disease.
Our major interest in this model was the cell-mediated autologous phase of disease characterized by the development of glomerular crescents and tubulointerstitial disease in association with macrophage and T-cell recruitment to the glomeruli and interstitium. During this phase, the expression of CCR2, CCR5, and CXCR3 was increased. In addition, levels of CCR1 mRNA expression increased further over that first seen during the heterologous phase, and persisted at elevated levels throughout the course of the disease. These various chemokine receptors are expressed by various leukocytes, but especially by macrophages (CCR1, CCR2, and CCR5) and T cells (CCR1, CCR2, CCR5, and CXCR3). Again, the temporal association between expression of these receptors and the influx of effector cells suggests that these receptors may play important roles in disease progression and are therefore suitable targets for interventional studies. Studies demonstrating the effectiveness of ligand neutralization support potential roles for some of these receptors (e.g., MCP-1/CCR2; RANTES/CCR1, CCR5) in NTN (11, 12) .
CCR1 was chosen as our initial target because it is highly expressed throughout disease and might thereby promote recruitment of macrophages, T cells, and neutrophils; and at least 3 of its ligands (MIP-1α, RANTES, and MCP-3) are expressed during the course of disease. Somewhat unexpectedly, when compared with CCR1 +/+ mice, CCR1 -/-mice developed more severe renal disease in terms of impairment of renal function, protein excretion, and histologic injury, including glomerular crescent formation. Recent studies have convincingly demonstrated that glomerular crescent formation is the result of a Th1 nephritogenic immune response (26) (27) (28) . For this reason, we compared the nature of the cell-mediated immune response in CCR1 -/-and CCR1 +/+ mice. By several criteria it appears that CCR1 -/-mice have a more powerful Th1-deviated immune response than that found in CCR1 +/+ mice, including more robust DTH responses to sheep IgG, antigen-specific IgG2a isotype production, and enhanced IFN-γ production by splenic T cells. Data from 2 nonrenal models also indicate that CCR1 has a role in directing the cell-mediated immune response. In a Schistosoma mansoni-induced lung granuloma model in CCR1 -/-mice (23), Gao et al. noted enhanced antigenspecific production of IFN-γ and reduced production of IL-4 by regional lymphoid cells, which is consistent with a Th1-predominant response. In addition, Kim et al. examined the effect of various chemokines on the immune response to DNA immunogens in mice (29) . Coimmunization of the DNA vaccine construct with a cDNA expression cassette encoding MIP-1α resulted in a Th2-polarized immune response (as determined by antigen-specific IgG isotype production), leading to the hypothesis that if this effect of MIP-1α is mediated through CCR1, as it appears from our own data, then the absence of CCR1 might favor a Th1 phenotype.
Compared with control mice, CCR1 -/-animals showed enhanced TNF-α and lymphotoxin mRNA expression in nephritic kidneys both early and late in the course of NTN, and in vitro CCR1 -/-splenocytes showed increased TNF-α production upon stimulation with LPS. Because TNF-α is a Th1-associated cytokine, the in vivo data may ultimately reflect the Th1-deviated response in CCR1 -/-mice. At the same time, the in vitro data leave open the possibility that CCR1 is involved in regulation of TNF-α production, potentially through an autocrine loop. In preliminary studies (data not shown), addition of CCR1 ligands did not diminish TNF-α production by LPS-stimulated mouse CCR1 +/+ macrophages, but further studies are necessary. Regardless of the mechanism responsible, TNF-α has been shown to play a critical role in the pathogenesis of glomerulonephritis (30) , suggesting that its enhanced production in CCR1 -/-mice could well contribute to the adverse outcome we observed.
The chemotaxis and binding studies show for the first time that in the mouse, RANTES and MCP-3 are not functional CCR1 ligands. This data helps to explain why the loss of CCR1 failed to prevent cell recruitment into the nephritic kidney, given the robust expression of RANTES and MCP-3 in this model. As in a previous report, MIP-1α -the only functional ligand for murine CCR1 according to our studies -was expressed to only a minor extent in this model (11) . This suggests that CCR1 is carried into the inflamed kidney by cells that are recruited through alternative chemotactic pathways (e.g., CCR2 or CCR5), highlighting the complexity and redundancy of this system. Taken with the functional effects of CCR1 deficiency in this system, the increased IFN-γ and associated IgG2a humoral responses, and the enhanced production of TNF and related cytokines in CCR1 -/-mice, our data suggest that the critical role of CCR1 in this model is not to promote chemotaxis but rather to facilitate and orchestrate the nature of cell-mediated immune responses. Caution is warranted in extrapolation of these data because findings from knockout mice do not necessarily predict events in wild-type animals in which the same pathway is blocked. However, in the absence of neutralizing antibodies or small molecules to inhibit CCR1 binding by its ligands in rodents, the data are both surprising and provocative.
In summary, this study shows the expression pattern of a number of chemokine receptors in a mouse model of crescentic glomerulonephritis, which will serve as a basis for future interventional studies. In addition, by examining the role of 1 of these prominently expressed chemokine receptors, CCR1, we have documented a redundant role in cell recruitment, but an unexpected and pathogenetically important role in modulating the effector phase of the immune response.
